RecruitingPhase 2NCT07211438

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Sponsor

Centre for Addiction and Mental Health

Enrollment

40 participants

Start Date

Jul 3, 2026

Study Type

INTERVENTIONAL

Conditions

Treatment Resistant Depression

Summary

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Psilocybin for people with treatment resistant depression. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.